X-ray structure determined from ex vivo Charcot-Leyden crystal

Experimental Data Snapshot

  • Resolution: 2.30 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.191 

wwPDB Validation   3D Report Full Report

This is version 1.1 of the entry. See complete history


Protein crystallization promotes type 2 immunity and is reversible by antibody treatment.

Persson, E.K.Verstraete, K.Heyndrickx, I.Gevaert, E.Aegerter, H.Percier, J.M.Deswarte, K.Verschueren, K.H.G.Dansercoer, A.Gras, D.Chanez, P.Bachert, C.Goncalves, A.Van Gorp, H.De Haard, H.Blanchetot, C.Saunders, M.Hammad, H.Savvides, S.N.Lambrecht, B.N.

(2019) Science 364

  • DOI: https://doi.org/10.1126/science.aaw4295
  • Primary Citation of Related Structures:  
    6GKQ, 6GKS, 6GKT, 6GKU, 6GLW, 6GLX, 6QRN

  • PubMed Abstract: 

    Although spontaneous protein crystallization is a rare event in vivo, Charcot-Leyden crystals (CLCs) consisting of galectin-10 (Gal10) protein are frequently observed in eosinophilic diseases, such as asthma. We found that CLCs derived from patients showed crystal packing and Gal10 structure identical to those of Gal10 crystals grown in vitro. When administered to the airways, crystalline Gal10 stimulated innate and adaptive immunity and acted as a type 2 adjuvant. By contrast, a soluble Gal10 mutein was inert. Antibodies directed against key epitopes of the CLC crystallization interface dissolved preexisting CLCs in patient-derived mucus within hours and reversed crystal-driven inflammation, goblet-cell metaplasia, immunoglobulin E (IgE) synthesis, and bronchial hyperreactivity (BHR) in a humanized mouse model of asthma. Thus, protein crystals may promote hallmark features of asthma and are targetable by crystal-dissolving antibodies.

  • Organizational Affiliation

    Immunoregulation Unit, VIB Center for Inflammation Research, Ghent, Belgium.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Galectin-10142Homo sapiensMutation(s): 1 
UniProt & NIH Common Fund Data Resources
Find proteins for Q05315 (Homo sapiens)
Explore Q05315 
Go to UniProtKB:  Q05315
PHAROS:  Q05315
GTEx:  ENSG00000105205 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ05315
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on GOL

Download Ideal Coordinates CCD File 
C3 H8 O3
Experimental Data & Validation

Experimental Data

  • Resolution: 2.30 Å
  • R-Value Free: 0.232 
  • R-Value Work: 0.187 
  • R-Value Observed: 0.191 
  • Space Group: P 65 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 48.941α = 90
b = 48.941β = 90
c = 258.337γ = 120
Software Package:
Software NamePurpose
XDSdata reduction
XDSdata scaling

Structure Validation

View Full Validation Report

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2019-06-05
    Type: Initial release
  • Version 1.1: 2024-01-17
    Changes: Data collection, Database references, Refinement description